The Terminator
Member
lol I didn’t really feel like going back thru the thread to find out
MESO-Rx
Anabolic Steroids
priapus (prp shot) for penis enhancement
- Thread starter bigboichoi
- Start date
lol I didn’t really feel like going back thru the thread to find out
I try not to dwell over it though.
lol I'm not gonna do that... but that was funny though
lol I'm not gonna do that... but that was funny though
I never had lipo - I think he's referring to ron jeremy.
I am really careful when it comes to getting work done. I asked the doctor a few times and called different ones. Also had different consultations. But the procedure didn't work for me. Luckily there is no damage either.
MisterSuperGod
New Member
@T-Bagger has been hounding me in PM to ask you this because he's afraid. Can you upload a picture of your non-normal penis?
Bump
I should have thought it over a couple more times before getting surgery.
The injections I mean
Platelet-Rich Plasma Therapy for Male Sexual Dysfunction: Myth or Reality?
Introduction Platelet-rich plasma (PRP) found its use in treating different conditions and diseases, because concentrated plasma PRP consists of many growth factors. Their interaction with surrounding cells, intracellular matrix, and mediators at the site of injection leads to tissue regeneration. Angiogenic, vasculogenic, and regenerative effects of PRP may be used for erectile dysfunction (ED) and Peyronie’s disease (PD) treatment.
Aim To present a current data review of preclinical and clinical trials on PRP use for treating ED and PD.
Methods Up-to-date literature on PRP use for ED and PD treatment was analyzed. The search was based on Pubmed, Cochrane Library, clinicaltrials.gov databases, with the following key words: “platelet-rich plasma” and/or “erectile dysfunction” and/or “Peyronie’s disease” and/or “sexual dysfunction.”
Main Outcome Measures The main outcome measures for preclinical trials on ED were erectile function, assessed with intracavernous pressure, and pathologic analysis of penile tissue. The main outcome measures for clinical trials on ED included penile duplex Doppler ultrasound scanning and validated questionnaires.
The main outcome measures on PD were pathologic analysis of penile tissue for preclinical trials, as well as penile duplex Doppler ultrasound scanning, penile curvature angle measuring, and validated questionnaires for clinical trials.
Results 4 preclinical and 6 clinical trials were described and analyzed in this article. Limitations for both preclinical and clinical trials included small groups, short follow-up periods, a lack of control groups or groups with placebo, and the lack of quality and quantity analysis of PRP.
Conclusion Available data show the lack of adverse reactions with PRP treatment. The studies that we found were limited by small groups. This is why the data on safety and effectiveness should be taken carefully. However, it is important to mention that PRP therapy has the potential for treating male sexual dysfunction and may be useful in andrology.
Epifanova MV, Gvasalia BR, Durashov MA, Artemenko SA. Platelet-Rich Plasma Therapy for Male Sexual Dysfunction: Myth or Reality? Sexual Medicine Reviews 2019. https://www.sciencedirect.com/science/article/pii/S2050052119300083
Introduction Platelet-rich plasma (PRP) found its use in treating different conditions and diseases, because concentrated plasma PRP consists of many growth factors. Their interaction with surrounding cells, intracellular matrix, and mediators at the site of injection leads to tissue regeneration. Angiogenic, vasculogenic, and regenerative effects of PRP may be used for erectile dysfunction (ED) and Peyronie’s disease (PD) treatment.
Aim To present a current data review of preclinical and clinical trials on PRP use for treating ED and PD.
Methods Up-to-date literature on PRP use for ED and PD treatment was analyzed. The search was based on Pubmed, Cochrane Library, clinicaltrials.gov databases, with the following key words: “platelet-rich plasma” and/or “erectile dysfunction” and/or “Peyronie’s disease” and/or “sexual dysfunction.”
Main Outcome Measures The main outcome measures for preclinical trials on ED were erectile function, assessed with intracavernous pressure, and pathologic analysis of penile tissue. The main outcome measures for clinical trials on ED included penile duplex Doppler ultrasound scanning and validated questionnaires.
The main outcome measures on PD were pathologic analysis of penile tissue for preclinical trials, as well as penile duplex Doppler ultrasound scanning, penile curvature angle measuring, and validated questionnaires for clinical trials.
Results 4 preclinical and 6 clinical trials were described and analyzed in this article. Limitations for both preclinical and clinical trials included small groups, short follow-up periods, a lack of control groups or groups with placebo, and the lack of quality and quantity analysis of PRP.
Conclusion Available data show the lack of adverse reactions with PRP treatment. The studies that we found were limited by small groups. This is why the data on safety and effectiveness should be taken carefully. However, it is important to mention that PRP therapy has the potential for treating male sexual dysfunction and may be useful in andrology.
Epifanova MV, Gvasalia BR, Durashov MA, Artemenko SA. Platelet-Rich Plasma Therapy for Male Sexual Dysfunction: Myth or Reality? Sexual Medicine Reviews 2019. https://www.sciencedirect.com/science/article/pii/S2050052119300083
Platelet-Rich Plasma and Treatment of Erectile Dysfunction: Critical Review of Literature and Global Trends in Platelet-Rich Plasma Clinics
Background Platelet-rich plasma (PRP) injections have recently been marketed as a form of autologous cell therapy under the banner of regenerative medicine despite limited scientific evidence on its use for treating erectile dysfunction (ED).
Aim To evaluate the evidence on PRP treatment for ED and determine the current trends in provision of this treatment.
Methods A critical review of the literature on PRP using the PubMed and Embase databases. Outcomes This narrative review focuses on the clinical use of, regulation of, and evidence for PRP in the treatment of ED.
Results There is a limited number of published peer-reviewed articles demonstrating clinical outcomes pertaining to the use of PRP for ED in human. The technique of PRP application for ED is currently patented, with a global total of 683 registered clinics. The majority of PRP clinics do not provide cost estimates on their websites.
Conclusion Despite a global presence of PRP clinics and ongoing active marketing and public interest in regenerative medicine, no scientific evidence has been published to establish an evidence-based risk-benefit profile for PRP use for ED in humans.
Given the limited data on clinical efficacy and potential harmful side effects, there is a need for a proper clinical trial to examine the role of PRP before it is accepted as standard of care in treatment for ED.
Scott S, Roberts M, Chung E. Platelet-Rich Plasma and Treatment of Erectile Dysfunction: Critical Review of Literature and Global Trends in Platelet-Rich Plasma Clinics. Sexual Medicine Reviews 2019. https://www.sciencedirect.com/science/article/pii/S2050052119300010
Background Platelet-rich plasma (PRP) injections have recently been marketed as a form of autologous cell therapy under the banner of regenerative medicine despite limited scientific evidence on its use for treating erectile dysfunction (ED).
Aim To evaluate the evidence on PRP treatment for ED and determine the current trends in provision of this treatment.
Methods A critical review of the literature on PRP using the PubMed and Embase databases. Outcomes This narrative review focuses on the clinical use of, regulation of, and evidence for PRP in the treatment of ED.
Results There is a limited number of published peer-reviewed articles demonstrating clinical outcomes pertaining to the use of PRP for ED in human. The technique of PRP application for ED is currently patented, with a global total of 683 registered clinics. The majority of PRP clinics do not provide cost estimates on their websites.
Conclusion Despite a global presence of PRP clinics and ongoing active marketing and public interest in regenerative medicine, no scientific evidence has been published to establish an evidence-based risk-benefit profile for PRP use for ED in humans.
Given the limited data on clinical efficacy and potential harmful side effects, there is a need for a proper clinical trial to examine the role of PRP before it is accepted as standard of care in treatment for ED.
Scott S, Roberts M, Chung E. Platelet-Rich Plasma and Treatment of Erectile Dysfunction: Critical Review of Literature and Global Trends in Platelet-Rich Plasma Clinics. Sexual Medicine Reviews 2019. https://www.sciencedirect.com/science/article/pii/S2050052119300010
T-Bagger
Member
Well, I am your alt handle, so just come clean and ask him from your original handle.
Thanks Dr. Scally for the information. I read through it in its entirety. I will do much more research before undergoing such a procedure in the future.
I still have pain in the injection sites. Who should I see about this?
Honestly it was stupid to get the procedure done but it was being offered by a doctor, and they told me it was safe before getting it done. I asked a few times because I wanted to make sure that it was ok to be done.
The Terminator
Member
A urologist, the dick is part of their specialty.
Roger rabbit
New Member
"In other words, it’s not okay to sell regenerative therapies for ED for a profit. I’d go substantially farther and say that in addition these “treatments” should not be used outside of a standard IND-based clinical trial process. The same goes for other regenerative sexual “therapies” that are not based on rigorous science."
SMSNA Position on Restorative Therapies for ED
http://www.smsna.org/V1/news/433-smsna-position-statement-on-restorative-therapies-for-ed
The SMSNA strongly supports the development of novel erectogenic therapies, given that many men with ED either fail currently available treatments or find them unpalatable. The society, however, recognizes the need for adequately powered, multicenter, randomized, sham/placebo-controlled trials in well-characterized patient populations to ensure that efficacy and safety are demonstrated for any novel ED therapy. The society agrees with the regulatory agency pathway of Phase I, II and III studies to achieve such a goal. Without FDA approval, the use of any novel therapy is considered off-label. The emergence of low intensity shock wave therapy (LiSWT), intracavernous stem cell therapy (SCT), intracavernous platelet rich plasma (PRP) therapy (and other agents such as amniotic fluid) represent a new frontier of investigative restorative therapies for ED treatment. In contrast to existing pharmacologic therapies that treat symptoms, therapies such as LiSWT, SCT, PRP represent potentially restorative modalities based on the concept that they might regenerate erectile tissues.
There exists robust basic science evidence in a variety of animal models (aged, diabetic, cavernous nerve injury) supporting the ability of LiSWT and SCT to improve erectile function. However, to date, there is an absence of robust clinical trial data supporting their efficacy and long-term safety in humans. Furthermore, the precise treatment parameters (energy settings, dosing, frequency of use, and duration of therapy among others) and cell source allowing optimization of these evolving therapies remain as yet, undefined. There exists only a small number of animal studies in a single model (cavernous nerve injury) establishing PRP as a potential erectogenic therapy. At this time, there are no human studies evaluating PRP as an erectogenic therapy.
Although several plausible and scientifically sound mechanisms of action have been proposed to explain how restorative therapies might improve erectile function, rigorous experimental data conclusively validating these mechanisms is currently lacking. This is in part because, unlike conventional pharmacologic therapies which generally have a primary, well-defined target, the mechanism of action of restorative therapies is likely to be complex involving a number of pathways inherent to the regenerative potential of the host. The SMSNA both advocates for and supports the application of high quality research, both pre-clinical and clinical, aimed at better understanding the mechanisms involved, the magnitude and durability of benefit and the long-term safety of restorative therapies.
Thus, given the current lack of regulatory agency approval for any restorative (regenerative) therapies for the treatment of ED and until such time as approval is granted, SMSNA believes that the use of shock waves or stem cells or platelet rich plasma is experimental and should be conducted under research protocols in compliance with Institutional Review Board approval. Patients considering such therapies should be fully informed and consented regarding the potential benefits and risks. Finally, the SMSNA advocates that patients involved in these clinical trials should not incur more than basic research costs for their participation.
SMSNA Position on Restorative Therapies for ED
http://www.smsna.org/V1/news/433-smsna-position-statement-on-restorative-therapies-for-ed
The SMSNA strongly supports the development of novel erectogenic therapies, given that many men with ED either fail currently available treatments or find them unpalatable. The society, however, recognizes the need for adequately powered, multicenter, randomized, sham/placebo-controlled trials in well-characterized patient populations to ensure that efficacy and safety are demonstrated for any novel ED therapy. The society agrees with the regulatory agency pathway of Phase I, II and III studies to achieve such a goal. Without FDA approval, the use of any novel therapy is considered off-label. The emergence of low intensity shock wave therapy (LiSWT), intracavernous stem cell therapy (SCT), intracavernous platelet rich plasma (PRP) therapy (and other agents such as amniotic fluid) represent a new frontier of investigative restorative therapies for ED treatment. In contrast to existing pharmacologic therapies that treat symptoms, therapies such as LiSWT, SCT, PRP represent potentially restorative modalities based on the concept that they might regenerate erectile tissues.
There exists robust basic science evidence in a variety of animal models (aged, diabetic, cavernous nerve injury) supporting the ability of LiSWT and SCT to improve erectile function. However, to date, there is an absence of robust clinical trial data supporting their efficacy and long-term safety in humans. Furthermore, the precise treatment parameters (energy settings, dosing, frequency of use, and duration of therapy among others) and cell source allowing optimization of these evolving therapies remain as yet, undefined. There exists only a small number of animal studies in a single model (cavernous nerve injury) establishing PRP as a potential erectogenic therapy. At this time, there are no human studies evaluating PRP as an erectogenic therapy.
Although several plausible and scientifically sound mechanisms of action have been proposed to explain how restorative therapies might improve erectile function, rigorous experimental data conclusively validating these mechanisms is currently lacking. This is in part because, unlike conventional pharmacologic therapies which generally have a primary, well-defined target, the mechanism of action of restorative therapies is likely to be complex involving a number of pathways inherent to the regenerative potential of the host. The SMSNA both advocates for and supports the application of high quality research, both pre-clinical and clinical, aimed at better understanding the mechanisms involved, the magnitude and durability of benefit and the long-term safety of restorative therapies.
Thus, given the current lack of regulatory agency approval for any restorative (regenerative) therapies for the treatment of ED and until such time as approval is granted, SMSNA believes that the use of shock waves or stem cells or platelet rich plasma is experimental and should be conducted under research protocols in compliance with Institutional Review Board approval. Patients considering such therapies should be fully informed and consented regarding the potential benefits and risks. Finally, the SMSNA advocates that patients involved in these clinical trials should not incur more than basic research costs for their participation.
Made in USA
Member
@bigboichoi did you do the recommended penis pump daily ?
I only ask because I had read up about this procedure and that was mentioned .
Also did you look into gainswave ?
I also read that they offer that along with prp.
I only ask because I had read up about this procedure and that was mentioned .
Also did you look into gainswave ?
I also read that they offer that along with prp.
I didn't do the penis pump because I was coming off cycle. But I did get the gainswave procedure and it did not work.
Anyway in the future I need to research and discuss issues with the doctor before attempting to get these procedures.
Anyway in the future I need to research and discuss issues with the doctor before attempting to get these procedures.
Roger rabbit
New Member
Lmfao!
So you didn’t follow instructions but blame the place.
Cracking me up over here.
Made in USA
Member
@bigboichoi
From the little research I did on it I believe the penis pump daily was a big part of the procedure being successful.
